PET, Imaging, and Tracer Development
Sources covering PET broadly: PET ligand parameters / dose / Steering Committee / workflow, immunoPET, 7T MRI, dopamine transporter imaging (DATscan, rodent), neuromelanin pigment / neuromelanin-MRI, VMAT-2 / [18F]AV-133, radiochemistry, and PET for astrocyte.
Source-of-truth pages live in data/processed/markdown/by-photo/. Each row below points first to the KB source note (which carries the heading list) and then to the canonical transcription.
Sources in this section: 16
Top-level nav clusters: 13
[MOLECULAR BIOLOGY]
3 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184809 | Page 1279 of 1292 | [MOLECULAR BIOLOGY] > [PET] > Parameters of PET ligand | note | md |
20240722_184823 | Page 1294 of 1309 | [MOLECULAR BIOLOGY] > [PET] > Parameters of PET ligand | note | md |
20240722_184836 | Page 1307 of 1318 | [MOLECULAR BIOLOGY] > [PET] > Regulatory Development Path PET ligand | note | md |
PET
2 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_183258 | Page 747 of 753 | PET | note | md |
20240722_184427 | Page 1060 of 1071 | PET > RBD (REM sleep behavior disorder) > Symptom > Incidence | note | md |
7T MRI
1 source page
[PHARMACOLOGY]
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184819 | Page 1290 of 1301 | [PHARMACOLOGY] > Parameters of PET ligand > Dose of PET tracer > PET Steering Committee > Workflow | note | md |
Dose of PET tracer
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184826 | Page 1300 of 1310 | Dose of PET tracer > PET Steering Committee > Workflow > Preclinical study | note | md |
NHP
1 source page
Parameters of PET ligand
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184816 | Page 1286 of 1298 | Parameters of PET ligand > Dose of PET tracer > PET Steering Committee > Workflow | note | md |
PE
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_183252 | Page 735 of 741 | PE > PET > Chemistry PET | note | md |
PET Steering Committee
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184829 | Page 1300 of 1311 | PET Steering Committee > Workflow > Preclinical study > Clinical study | note | md |
Pipeline
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184424 | Page 1060 of 1071 | Pipeline > Radiochemical > Rare Disease > PET | note | md |
PK-PD relationship
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184813 | Page 1283 of 1295 | PK-PD relationship > [PET] > Antibody radiolabelling > Parameters of PET ligand | note | md |
Terminology
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184420 | Page 1057 of 1066 | Terminology > Psychosis in PD > pipeline > Radiochemical | note | md |
VMAT Vesicular monoamine transporter-2
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184604 | Page 1147 of 1162 | VMAT Vesicular monoamine transporter-2 > VMAT PET > [18F]AV-133 | note | md |